Kornimate/medical-research-clean huggingface dataset:
medium calorie parenteral nutrition on patients with gastrointestinal cancer undergoing surgery

Conditions: Colorectal Neoplasms

Summary: aimed at investigating the efficacy, safety, and clinical outcome of medium-calorie or standard-calorie total parenteral nutrition (tpn) for patients with gastrointestinal cancer undergoing surgery

biochemistry data various inflammation-related cytokines clinical outcome hospital stay

Eligibility criteria:
inclusion criteria: * patients considered for major surgery for colorectal cancer expected requirement for post operative pn or tpn of at least for 7 days age \>18 hemodynamically stable written informed consent exclusion criteria: * hemodynamic failure of any organ renal insufficiency patients with severe liver dysfunction albumin \< 3g/dl dm with poor blood sugar control

Keywords: medium-calorie standard calorie parenteral nutrition
efficacy and safety study of panobinostat in participants with metastatic hormone refractory prostate cancer

Conditions: Prostate Cancer

Summary: this phase ii single dose study was designed to characterize the safety, tolerability, and efficacy of intravenous (i.v.) panobinostat as a single-agent treatment in participants with hormone refractory prostate cancer.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of adenocarcinoma of the prostate * participants with metastatic hormone refractory prostate cancer * participants that have had at least one, but not more than two prior cytotoxic treatments for prostate cancer * evidence of disease progression by at least one of the following: 1. two or more lesions on bone scan 2. progressive measurable disease 3. two documented increases in prostate-specific antigen (psa) * willing to use contraception throughout the study and for 12 weeks after study completion exclusion criteria: * history or clinical signs of central nervous system (cns) disease * history of other cancers not curatively treated with no evidence of disease for more than 5 years * prior radiotherapy within 3 weeks of starting study treatment * prior radiopharmaceuticals (strontium, samarium) * impaired cardiac function * heart disease * liver or renal disease with impaired function other protocol-defined inclusion/exclusion criteria may apply.

Keywords: prostate cancer adenocarcinoma prostate-specific antigen metastatic male hrpc daci
algorithm to control postprandial, post exercise and night glucose excursions in a portable closed loop format,

Conditions: Diabetes Mellitus, Type 1

Summary: in previous studies, the investigators tested the feasibility of a bi-hormonal reactive closed loop system without mealtime announcement. this system for automated control of blood glucose in patients with type 1 diabetes was tested in the clinical research center (appel 1 and 2) as well as at the home of the patients (appel 3 and 4). after the appel 4 study some improvements have been made to the miniaturized prototype to allow patients to operate the system independently and additional risk control measures were included. the main objective of this study is to assess the efficacy of this improved closed loop system.


Eligibility criteria:
inclusion criteria: * diagnosed with diabetes mellitus type 1; * treated with sap or csii for a minimum of 6 months; * willing and able to sign informed consent. exclusion criteria: * impaired awareness of hypoglycemia (score ≥ 4) according to gold and/or clarke questionnaire; * bmi \> 35 kg/m2; * hba1c \> 97 mmol/mol (=11.0 %); * use of heparin, coumarin derivatives or oral corticosteroids; * use of acetaminophen during the open loop or closed loop period, as this may influence the sensor glucose measurements; * limited ability to see, and to hear or feel alarm signals of the closed loop system; * skin condition prohibiting needle insertion; * pregnancy and/or breastfeeding; * living alone during the night during the closed loop period (the patient may ask someone to stay over temporarily); * expected poor connectivity with internet regarding 24/7 tele monitoring; * any condition that the local investigator feels would have interfere with trial participation or the evaluation of the results

Keywords: artificial pancreas glucose control
effect of angiotensin receptor blockade on insulin resistance and adipose tissue cytokines in type 2 diabetes

Conditions: Insulin Resistance; Type 2 Diabetes

Summary: the study aims to investigate the effect of acute angiotensin receptor blockade on insulin action/insulin resistance and expressions of selected adipocytokines in subcutaneous adipose tissue in insulin-resistant subjects with type 2 diabetes and healthy controls. hypothesis: changes in adipocytokine concentrations and/or expressions and different reactions to acute in vivo induced hyperinsulinemia and angiotensin receptor blockade will be found in patients with type 2 diabetes compared to healthy subjects. a significant relationships between insulin sensitivity and selected adipokines and intracellular fat content and high energy phosphates in soleus muscle will be documented in healthy individuals, while no significant relation will be found in patients with type 2 diabetes.

10-15 patients with type 2 diabetes and 10-15 healthy control subjects will be examined on an outpatient basis. the following examination will be carried out in each subject after 12 hrs fasting: * oral glucose tolerance test (75 g of glucose) (in healthy subjects to confirm the normal tolerance of glucose). * evaluation of insulin secretion after 1 mg of glucagon i.v. * hyperinsulinaemic (75 milly-international unit(miu)/l) euglycemic clamp study lasting 4 hours combined with indirect calorimetry and biopsy of subcutaneous adipose tissue. * hyperinsulinemic (75 miu/l) euglycemic clamp study lasting 4 hours combined with indirect calorimetry after losartan 100 mg given in the evening and in the morning before the study. * proton and phosphorus magnetic resonance spectroscopy. before (0 min), at 30 min and in the end of studies c) and d) the blood samples will be taken and biopsies of subcutaneous abdominal adipose tissue will be done.

Eligibility criteria:
inclusion criteria: 1. type 2 diabetes treated with oral agents and/or diet 2. healthy volunteers age- and sex-matched to type 2 diabetes, without any concomitant disease exclusion criteria: 1. type 2 diabetes * treated with insulin * clinical evidence of atherosclerotic complications * advanced long-term diabetic complications (manifest nephropathy, proliferative retinopathy) * other internal disease * weight change \>10% 3 months prior to study 2. healthy volunteers * fulfilling the criteria of metabolic syndrome * weight change \>10% 3 months prior to study

Keywords: adipose tissue adipokines
effects of soy protein on serum paraoxonase1 activity and lipoproteins in postmenopausal women

Conditions: Postmenopausal; Hyperlipidemia

Summary: paraoxonase 1 is involved to prevent ldl and hdl oxidation,so increase of it's activity leads to lower risk of coronary heart disease.in postmenopausal women ,we have decrease of paraoxonase1 activity and soy proteins may increase paraoxonase1 activity

in a double blind clinical randomised clinical trial with parallel design this study was done.52 postmenopausal women were randomly assigned to 50 g/d soy protein or placebo for 10 weeks.serum lipoproteins and pon1 activity were measured at baseline and 10th week.there were significant increase in pon! activity and significant decrease in ldl-c,ldl-c/hdl-c,tc/hdl-c and tg/hdl-c in soy group compare to placebo group.

Eligibility criteria:
inclusion criteria: * cessation of menes for more than 1 year, elevation for more than 1 year * elevation of fsh level * total cholesterol * triglyceride more than 200 mg/dl exclusion criteria: * chronic disease (heart disease, cancer, diabetes, hepatic, kidney and thyroid disease) * antihypertensive drugs * antibiotics * lipid lowering drugs * sex hormone treatment * hysterectomy * diet rich in soy protein

Keywords: paraoxonase1 activity ldl hdl postmenopausal women postmenopausal women and hyperlipidemia
effectiveness of toothpaste containing the active ingredient of galla chinensis extract on treating dentin hypersensitivity

Conditions: Tooth Sensitivity

Summary: this clinical trial was conducted to compare the desensitizing effect of toothpaste containing the active ingredient of an extract of galla chinensis and toothpaste containing fluoride in patients with dentin hypersensitivity.


Eligibility criteria:
inclusion criteria: * age \>18 years. * overall good oral hygiene status. * participants show tooth neck abrasion or gingival retraction. * patients have subjective dentin hypersensitivity (at least 1 tooth) after using airflow. * no history of periodontal treatment, including periodontal surgery, in the past year. * written informed consent exclusion criteria: * patient with severe periodontitis or severe erosion damage. * patients with a compromised medical history, or had received therapeutic irradiation to the head and neck region. * medically compromised patients where pain levels would be compromised. * if analgesics or antibiotics have been administrated by the patient during the past 12 hours preoperatively as it might alter their pain perception. * patients reporting bruxism or clenching in order to avoid further pressure on an already hypersensitive tooth inducing subsequent irritation and inflammation. * teeth that show association with acute periapical abscess and swelling. * greater than grade i mobility or pocket depth greater than 5mm. * non-restorable teeth or hopeless teeth. * immature teeth. * radiographic evidence of external or internal root resorption. * alcoholic and smoker patients. * pregnant or breastfeeding ladies. * patients having physical disabilities, or who are unable to brush their teeth * patients who have a history of allergies to any personal oral care product or ingredient, or who are taking anti-inflammatory drugs within the previous month. * individuals who had sensitive teeth but with one of the following conditions will be excluded from the study, teeth with large restorations, abutment of teeth of removable partial dentures, dental caries, enamel cracks, leakage of fillings or other restorations, cracked 23 * teeth, dental pulp lesions, dental abscesses, pulpitis, and atypical facial pain. * patients had participated in a clinical trial within 6 months before commencement of this trial. * patients unable to return for recall appointment.
ultrasound guided bilateral superficial cervical block for post-operative pain therapy in thyroid surgery

Conditions: Bilateral Superficial Cervical Block

Summary: ultrasound guided bilateral superficial cervical block for postoperative pain therapy in thyroid surgery


Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) class i and ii exclusion criteria: * allergy to local anesthetics, bleeding diatheses, and local infection or sepsis thyrotoxicosis and , malignancy.
cognitive de-biasing and the assessment of pediatric bipolar disorder

Conditions: Decision Making; Bipolar Disorder

Summary: the primary aim is to test the efficacy of a new intervention to improve clinical judgment. the investigators focus on the assessment of pediatric bipolar disorder (pbd), a controversial diagnosis with frequent diagnostic errors, by educating mental health professionals in common cognitive pitfalls and training them in recommended de-biasing strategies. the investigators hypothesize that the treatment group will show higher diagnostic accuracy than the control condition: participants receiving the cognitive de-biasing intervention will be less likely to commit faulty heuristics and race/ethnicity bias. secondary aims include soliciting feedback about whether the skills were useful when diagnosing the vignettes, and whether skills and cases seem clinically realistic.

a randomized controlled trial (rct) of 100 participants will test the efficacy of a new intervention to improve clinical judgment. eligible participants will be licensed or currently supervised by a licensed mental health professional and have experience working with pediatric populations. participants will be randomly assigned to either treatment or control conditions. all participants receive a 5 minute pre-recorded presentation about mood disorders, then read several case vignettes and respond to questions regarding judgments about probable diagnoses and next clinical actions. study administration is web-based via a secure portal. after answering questions to confirm eligibility and provide informed consent, participants will complete a background questionnaire. the web software, qualtrics, will randomize participants to watch a brief presentation on mood disorders (i.e., control condition) versus the same presentation on mood disorders combined with the intervention (i.e., treatment condition). the intervention is a 20-minute training on decision-making errors and cognitive de-biasing strategies. next, all participants review four clinical vignettes. using only four vignettes reduces participant burden and maximizes response rate. qualtrics presents the case vignettes in random orders. after completing the last vignette and corresponding questions, participants in the treatment condition rate their experience of the intervention. these questions address the secondary study aims: (a) how participants will use these new techniques in their clinical practice; and, (b) how the investigators can tailor the intervention to make it even more user-friendly and appealing to clinical audiences.

Eligibility criteria:
inclusion criteria: * participants need to be: (a) licensed or currently supervised by a licensed mental health professional; and, (b) have experience treating child and adolescent patient populations for mental health issues. exclusion criteria: * not meeting criterion (a) or (b) above.

Keywords: decision making pediatric bipolar disorder assessment intervention
improving health literacy in african-american prostate cancer patients

Conditions: Prostate Cancer

Summary: investigators propose an observational interview study to explore how patients understand treatment conversations with their physicians within the framework of health literacy. the study team will test whether patients' understanding of treatment options and side effects can be improved when patients receive a low literacy educational supplement after meeting with their urologist. investigators will interview a group of newly diagnosed, early stage, african american prostate cancer patients.

investigators propose an observational interview study to explore how patients understand treatment conversations with their physicians within the framework of health literacy. the study team will test whether patients' understanding of treatment options and side effects can be improved when patients receive a low literacy educational supplement after meeting with their urologist. investigators will interview a group of newly diagnosed, early stage, african american prostate cancer patients. investigators hypothesize that the delivery of a scripted, tailored, low literacy educational supplement will result in a statistically significant decrease in decisional conflict, and a statistically significant improvement in comprehension of cancer treatment and its side effects compared to standard practice. the study team will measure patients' comprehension of treatment options and side effects, as well as decisional conflict; after standard practice, and again after exposure to the educational supplement. investigators will compare the urologists' assessment of patients' 1) health literacy 2) preferences for side effects 3) stage of decision making, 4) treatment choice or predisposition toward treatment choice. 5) preference for role in decision making (active, passive, or shared with physician); to measures obtained from patients. these comparisons will allow investigators to quantify the potential benefit to the physician of information obtained through the interview and low literacy educational supplement.

Eligibility criteria:
inclusion criteria: * patients who have undergone pathology review of their prostate biopsy at emory university, grady memorial hospital, saint joseph's hospital, and atlanta va medical center with ajcc clinical stage t1-t2 prostate cancer by physical exam exclusion criteria: * rn or md degree * history of head injury or dementia * history of cognitive impairment * unable to undergo the informed consent process and the study interview in english per the judgment of the primary urologist or urological provider

Keywords: urology
prevalence of central neuropathic pain after a stroke in patients attending post-stroke consultations in the île-de-france region

Conditions: Stroke Sequelae; Neuropathic Pain

Summary: post-stroke pain is common, affecting 15-50% of patients and significantly impacting their quality of life, rehabilitation, and functional recovery. there are different types of post-stroke pain, including peripheral pain related to spasticity, shoulder pain, complex regional pain syndrome, and headaches, as well as central pain linked to brain lesions. central post-stroke pain (cpsp) is diagnosed when the pain has neuropathic characteristics (burning, cold, tightness, compression), possibly accompanied by allodynia, hyperesthesia, and sensory-motor disorders localized to the area affected by the stroke. cpsp disrupts sleep, impairs functional rehabilitation, and can lead to depression, anxiety, substance abuse, and cognitive disorders. the prevalence of cpsp varies, ranging from 1% to 35%, but it is likely underreported due to difficulties in detection caused by cognitive or communication issues, the clinical variability of cpsp, and its coexistence with other types of post-stroke pain. cpsp often remains resistant to standard neuropathic pain treatments, such as anticonvulsants and antidepressants, which may cause side effects that reduce patients' autonomy and quality of life. non-pharmacological therapies used in other chronic pain conditions may offer promising alternatives, but have not been widely studied in cpsp. improved clinical characterization of cpsp patients is essential. following a 2015 decree by the french ministry of health, post-stroke consultations are standardized, providing a good opportunity for systematic pain screening. the study proposes a systematic screening of different types of pain during post-stroke consultations, categorizing patients into three groups: those with cpsp, those with pain from another mechanism, and those without pain.


Eligibility criteria:
inclusion criteria: * patient aged ≥18 years * patient attending a post-stroke consultation (3 to 6 months after the stroke) * stroke confirmed by imaging (mri or ct scan) * francophone patient * patient not opposing participation in the study exclusion criteria: * patient with cognitive or communication disorders preventing them from completing the questionnaires (as assessed by the investigator) * patient under guardianship or curatorship * patient deprived of liberty * patient under judicial protection
petro-trigeminal line and petrous apex cephaloceles

Conditions: Petrous Apex Meningioma

Summary: cephaloceles are rare lesions of the petrous apex, inconsistently listed as meningoceles or arachnoid cysts. they're consistent with a herniation posterolateral of the meckel cavum within the petrous apex. these lesions may be the cause of a symptomatology varied, or be discovered by chance in subjects who have not been asymptomatic. currently, there is no evidence in the literature a simple, fast and reproducible radiological marker that allows for the diagnosis of cephaloceles of the petrous apex, in particular the small ones. the purpose of this study is to validate a radiological benchmark simple and reproducible, the trigeminal petrol line, in order to improve the diagnosis of petrous apex cephaloceles


Eligibility criteria:
inclusion criteria: * major subjects (≥18 years old) * patients who underwent an mri with high resolution 3d t2 sequence between 01/01/2003 and 09/31/2020: * 200 patients consulting for ent pathology such as vertigo * 9 patients presenting the radiological criteria in mri of a cephalocele of the petrous apex according to the current data of the literature on a t2 3d hr sequence * - subject who has not expressed his opposition, after being informed, to the reuse of his data for the purposes of this research. exclusion criteria: * subject who expressed their opposition to participating in the study * kinetic artifacts * subject under guardianship or curatorship * subject under safeguard of justice

Keywords: petrous apex cephaloceles petrous apex meckel's cave cavum-trigeminale-cephaloceles arachnoïd kyst meningoceles trigeminal nerves
study comparing immunogenicity, reactogenicity and safety of gsk bios' hbv-mpl vaccine with that of engerix™-b in adults

Conditions: Hepatitis B

Summary: this study is conducted to compare the immunogenicity, reactogenicity and safety of engerix™-b and hbv-mpl vaccine against hepatitis b infection in an elderly population

at the time of conduct of this study, the sponsor glaxosmithkline was known by its former name smithkline beecham

Eligibility criteria:
inclusion criteria: * age: 50 to 70 years old. * good physical condition as established by clinical examination and history taking at the time of entry. * female participants who are at risk to become pregnant will be on a contraceptive programme if necessary during the study period. * written informed consent obtained from the subjects exclusion criteria: * positive at screening for anti-hbv antibodies. * elevated serum liver enzymes * history of significant and persisting hematologic, hepatic, renal, cardiac or respiratory disease. * any acute disease at the moment of entry. * chronic alcohol consumption. * hepatomegaly, right upper quadrant abdominal pain or tenderness. * any chronic drug treatment, including any treatment with immunosuppressive drugs, which in the investigator's opinion, precludes inclusion into the study. * history of allergic disease likely to be stimulated by any component of the vaccine. * simultaneous participation in any other clinical trial. * previous vaccination with a recombinant hepatitis b vaccine. * previous vaccination with an mpl containing vaccine. * administration of immunoglobulins in the past 6 months and during the whole study period * vaccination one week before and one week after each dose of the study vaccine

Keywords: adjuvanted hepatitis b vaccine, hepatitis b, engerix™-b